Dermatology and therapy · 2026
Achieving Minimal Disease Activity in Atopic Dermatitis Is Associated with Fewer Flares, Reduced Healthcare Resource Utilization, and Improved Disease Control: Analysis from the Real-World MEASURE-AD Study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Silverberg Jonathan I, Prajapati Vimal H, Abraham Susanne, Irvine Alan D, Gooderham Melinda J, Guttman-Yassky Emma, Tanizaki Hideaki, Rademaker Marius, Chen Shirley H, Moreira Alvaro, Ta Richard, Lee Wan-Ju, Eyerich Kilian
Аннотация
INTRODUCTION: Atopic dermatitis (AD), a chronic inflammatory condition, is the leading cause of global burden from skin disease. Optimal targets for clinician-reported outcomes (ClinROs) and patient-reported outcomes (PROs), including minimal disease activity (MDA; defined as simultaneous achievement of ≥ 1 optimal ClinRO and ≥ 1 optimal PRO), were established following the Aiming High in Eczema/Atopic Dermatitis (AHEAD) initiative. This study evaluated the impact of MDA achievement on flare activity, healthcare resource utilization, and patient-reported disease control in adults with moderate-to-severe AD.
METHODS: This retrospective post hoc analysis used data from the real-world cross-sectional MEASURE-AD study and included adults with moderate-to-severe AD across 28 countries. Three definitions were used to identify achievement of MDA. Outcomes were measured using patient-reported questionnaires evaluating flare activity and healthcare resource utilization over the preceding 6 months, as well as patient-reported disease control assessed at the time of the questionnaire. Statistical analyses compared patients achieving MDA targets with non-MDA groups using Kruskal-Wallis tests.
RESULTS: Patients achieving MDA experienced fewer flares (means ranging from 0.8 to 1.4) compared with non-MDA groups (3.8-9.8) over the preceding 6 months. Flares were shorter in duration, with 9.9-13.4% of patients who achieved MDA reporting flares longer than 7 days compared with 26.4-51.1% of patients across non-MDA groups. Patients who met neither optimal ClinRO or PRO reported a 2.2- to 2.7-fold increase in average number of healthcare visits compared with MDA groups. More patients who achieved MDA indicated complete agreement that their AD was effectively controlled (86.7-94.2%) compared with those who did not achieve MDA (19.2-74.1%).
CONCLUSIONS: Achievement of MDA in patients with moderate-to-severe AD was associated with less frequency and duration of flares, reduced healthcare resource utilization, and increased patient-reported disease control compared with those who did not achieve MDA. These findings emphasize the importance of holistic assessments when evaluating treatment outcomes in AD.
TRIAL REGISTRATION: ClinicalTrials.gov Identifiers NCT03569293 (Measure Up 1), NCT03607422 (Measure Up 2), and NCT03568318 (AD Up).
METHODS: This retrospective post hoc analysis used data from the real-world cross-sectional MEASURE-AD study and included adults with moderate-to-severe AD across 28 countries. Three definitions were used to identify achievement of MDA. Outcomes were measured using patient-reported questionnaires evaluating flare activity and healthcare resource utilization over the preceding 6 months, as well as patient-reported disease control assessed at the time of the questionnaire. Statistical analyses compared patients achieving MDA targets with non-MDA groups using Kruskal-Wallis tests.
RESULTS: Patients achieving MDA experienced fewer flares (means ranging from 0.8 to 1.4) compared with non-MDA groups (3.8-9.8) over the preceding 6 months. Flares were shorter in duration, with 9.9-13.4% of patients who achieved MDA reporting flares longer than 7 days compared with 26.4-51.1% of patients across non-MDA groups. Patients who met neither optimal ClinRO or PRO reported a 2.2- to 2.7-fold increase in average number of healthcare visits compared with MDA groups. More patients who achieved MDA indicated complete agreement that their AD was effectively controlled (86.7-94.2%) compared with those who did not achieve MDA (19.2-74.1%).
CONCLUSIONS: Achievement of MDA in patients with moderate-to-severe AD was associated with less frequency and duration of flares, reduced healthcare resource utilization, and increased patient-reported disease control compared with those who did not achieve MDA. These findings emphasize the importance of holistic assessments when evaluating treatment outcomes in AD.
TRIAL REGISTRATION: ClinicalTrials.gov Identifiers NCT03569293 (Measure Up 1), NCT03607422 (Measure Up 2), and NCT03568318 (AD Up).